Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00676026 · ClinicalTrials.gov registry record · NA
Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00676026: Completed NA study, sponsored by University of Pennsylvania.
NCT00676026 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00676026, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this series of challenge studies is to examine the impact of menstrual cycle phase on cortical GABA response to administration of agents with either direct (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While the impact of these agents on cortical GABA levels in women with premenstrual dysphoric disorder (PMDD) is of interest, this study is designed primarily for those women without a psychiatric illness.
Interventions
- DRUG Progesterone
- DRUG Zolpidem
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2005-05 |
| Est. Completion | 2009-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00676026
The ClinicalTrials.gov registry entry for NCT00676026 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Progesterone is the first listed.
NCT00676026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00676026 about?
NCT00676026 is a clinical study titled "Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women". The goal of this series of challenge studies is to examine the impact of menstrual cycle phase on cortical GABA response to administration of agents with either direct (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While the impact of these agents on cortical GA...
What is the current status of trial NCT00676026?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2005-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00676026?
The interventions under investigation include: Progesterone (DRUG), Zolpidem (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00676026?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.